Intended for healthcare professionals

Editorials

Statins and The BMJ

BMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g5038 (Published 07 August 2014) Cite this as: BMJ 2014;349:g5038

Re: Statins and The BMJ

Dear Sir,

Another trial needing some scrutinity is SPARCL, a stroke-tia secondary prevention trial demonstrating some effect of atorvastatin 80 mg on the recurrence of ischemic stroke. I never found out why the marginal benefits (NNT > 200) of atorvastatin found their way into guidelines.

Another miracle was, why on earth there was there no overall survival benefit of this kind of statin in mostly above 70 stroke patients who should bear their share of IHD etc.

Is there really no difference between the overall effects of "natural" and "synthetic" statins ?

Kind regards

Joerg Wiesenfeldt

Competing interests: No competing interests

29 October 2015
Joerg Wiesenfeldt
Staff Grade Neurologist
Verbundkrankenhaus Bernkastel-Wittlich
Koblenzer Str. 91, Wittlich, 54516, Germany